Jump to Main Contents
ncc en
HOME > Publication & Reports > Annual Report 2024 > Hospital East

Annual Report 2024

Department of General Internal Medicine

Yoichi Naito, Yasutoshi Kuboki, Tomofumi Miura, Kensuke Shinmura, Tetsuya Sakai, Saori Mishima, Hiromichi Nakajima, Taro Shibuki

Introduction

 We provide general management across cancer types and support for medical treatment in each department (management for complications, adverse events, etc.). Our practice also aims to foster the development of specialists involved in cancer care.

 As a teaching hospital affiliated with the Japanese Society of Internal Medicine, we accept and train trainees who are pursuing certification as internal medicine specialists.

 With the expanding indications for immune checkpoint inhibitors across a wide range of diseases and the increasing clinical experience with these agents, we have accumulated substantial experience in managing immune-related adverse events (irAEs). Furthermore, with the recent clinical introduction of therapies such as chimeric antigen receptor (CAR) T cells and T-cell engagers, we have encountered cases of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). In collaboration with all the departments, including the Department of Pharmacy and the Department of Nursing, we monitor the occurrence of irAEs, CRS, and ICANS and implement appropriate management strategies.

 We also support research related to irAEs (including collaborations with the pharmacy department), and provide consultations for drug-induced kidney injury and other renal complications.

The Team and What We Do

  • Increased number of reported irAEs, CRS, and ICANS (Figure 1)

Figure1.Number of irAE/CRS/ICANS
Figure1.Number of irAE/CRS/ICANS

Figure1.Number of irAE/CRS/ICANS
Figure1.Number of irAE/CRS/ICANS
  • Implementation of irAE collaboration seminar
  • Revision of a manual for immune checkpoint inhibitors
  • Development of manual for drug-induced liver injury and plasma exchange
  • Development of manual for acute kidney injury and plasmapheresis

Research Activities

  • Contribution to the training of internal medicine trainees
  • Case presentation support for trainees at the congress of the Japanese Society of Internal Medicine or related congress
  • Paper writing support
  • Intensive lectures on medical oncology for new residents (updated)
  • Support/guidance for new research (e.g., observational study to confirm the pharmacokinetics of mycophenolate mofetilfor liver damage caused by immune checkpoint inhibitors)
  • irAE cooperation seminar with regional institutions
  • Conducting clinical trials related to supportive care

Clinical Trials

  • An observational study is currently planned in collaboration with the Department of Dermatology.
  • multicenter observational study on immune-related adverse events (irAEs) is currently planned.

Education

 We will further collaborate with regional institutions to gather outstanding trainees, and develop close connections with several academic institutions. We will revise a manual for immune checkpoint inhibitors, and develop safe and cost-effective practice. We plan to have approximately 100 case consultations on immune related AEs.

Future Prospects

 We will continue to provide high-quality training. The medical treatment for cancer at our hospital is at the top level in Japan, and we will continue to improve the medical treatment system so that the valuable experience gained at this hospital can be returned to general medical treatment, and to establish a consulting system. We will continue the irAE cooperation program and promote research planning for issue identification and improvement. We will deepen our cooperation with the Department of Pharmacy and Department of Nursing, and continue our efforts to share and improve issues within the hospital.

 We will further focus on management for adverse events caused by various drugs, in-hospital and out-of-hospital collaboration. We will prepare a manual on renal failure and hemodialysis, train personnel who will be a consultant for renal failure, and establish a cooperative system with collaborating facilities.

 Regarding education, we will cooperate with the Human Resource Development Center to enhance internal education and will continuously cooperate with external parties. We will continuously confirm that medical issues can be shared with the risk management department.

List of papers published in 2024

Journal

1. Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. Journal of thoracic oncology, 20:177-193, 2025

2. Watanabe T, Murano T, Ikematsu H, Shinmura K, Wakabayashi M, Minakata N, Maasa S, Mitsui T, Yamashita H, Inaba A, Sunakawa H, Nakajo K, Kadota T, Yano T. Impact of advanced endoscopy training on colonoscopy quality and efficiency. DEN open, 5:e70027, 2025

3. Ikematsu H, Takara Y, Nishihara K, Kano Y, Owaki Y, Okamoto R, Fujiwara T, Takamatsu T, Yamada M, Tomioka Y, Takeshita N, Inaba A, Sunakawa H, Nakajo K, Murano T, Kadota T, Shinmura K, Koga Y, Yano T. Possibility of determining high quantitative fecal occult blood on stool surface using hyperspectral imaging. Journal of gastroenterology, 60:77-85, 2025

4. Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, Uenaka T, Doi T, Yasunaga M. Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug Distribution. Molecular cancer therapeutics, 24:242-250, 2025

5. Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric cancer, 28:63-73, 2025

6. Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, Yoshino T, Sasser K, Oki E, Nimeiri H. A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan. Clinical cancer research, 31:328-338, 2025

7. Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. NETosis in pulmonary pleomorphic carcinoma. Cancer science, 116:524-532, 2025

8. Iwata H, Naito Y, Hattori M, Yoshimura A, Yonemori K, Aizawa M, Mori Y, Yoshimitsu J, Umeyama Y, Mukohara T. Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study. International journal of clinical oncology, 30:72-82, 2025

9. Bando H, Naito Y, Yamada T, Fujisawa T, Imai M, Sakamoto Y, Saigusa Y, Yamamoto K, Tomioka Y, Takeshita N, Sunami K, Futamura M, Notake C, Aoki S, Okano K, Yoshino T. A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device. International journal of clinical oncology, 30:172-179, 2025

10. Ito Y, Zenke Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Umemura S, Matsumoto S, Yoh K, Nakamura M, Hojo H, Izumo T, Goto K. A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score). Future oncology (London, England), 21:473-481, 2025

11. Gotoh R, Shimizu Y, Hayashi A, Isseki M, Miura T, Inoue A, Takano M, Masukawa K, Aoyama M, Morita T, Kizawa Y, Tsuneto S, Shima Y, Miyashita M. Associations Between Anticipatory Grief and Post-Bereavement Depression and Post-Loss Grief of Family Members of Dying Patients With Cancer in Palliative Care Units: A Cohort Study. The American journal of hospice & palliative care, 10499091241313299, 2025

12. Katsuya Y, Ikeda M, Koyama T, Sato J, Okada M, Matsubara N, Kondoh C, Mukohara T, Watanabe K, Kotani D, Ogawa Y, Taoka S, Yamamoto N. A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors. Cancer science, 116:1012-1022, 2025

13. Misawa S, Denda T, Kodama S, Suzuki T, Naito Y, Kogawa T, Takada M, Hino A, Shiosakai K, Kuwabara S. One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study). Expert opinion on pharmacotherapy, 26:335-344, 2025

14. Imamura S, Watanabe K, Inoue K, Taira T, Shibuki T, Satake T, Yamaguchi S, Sasaki M, Imaoka H, Mitsunaga S, Ikeda M. Side-by-side versus stent-in-stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction. DEN open, 5:e70075, 2025

15. Amano K, Okamura S, Miura T, Baracos VE, Mori N, Sakaguchi T, Uneno Y, Ishiki H, Hiratsuka Y, Yokomichi N, Hamano J, Baba M, Mori M, Morita T. Clinical Implications of the C-Reactive Protein-Albumin Ratio as a Prognostic Marker in Terminally Ill Patients with Cancer. Journal of palliative medicine, 28:592-600, 2025

16. Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, Tanaka Y, Habu T, Fukaya S, Kondo M, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukui M, Fuse N, Koyama S, Mano H, Nishikawa H, Shitara K, Yoshino T, Kojima T. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). Nature cancer, 6:445-459, 2025

17. Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, Umemura S, Zenke Y, Matsumoto S, Yoh K, Kubota S, Aokage K, Sakamoto N, Sakashita S, Kojima M, Nagamine M, Hosomi Y, Tsuboi M, Goto K, Ishii G. Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO clinical and research reports, 6:100779, 2025

18. Naito Y, Iwagami S, Doi T, Takahashi T, Kurokawa Y. Pimitespib in patients with advanced gastrointestinal stromal tumors in Japan: an expanded access program. International journal of clinical oncology, 30:935-943, 2025

19. Uehara Y, Izumi H, Kobayashi IS, Matsumoto S, Hosomi Y, Okuno T, Sugisaka J, Takase N, Taima K, Sasaki S, Teranishi S, Miyamoto S, Mori M, Nakashima C, Asano S, Oi H, Sakai T, Shibata Y, Udagawa H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Ikeda S, Costa DB, Kobayashi SS, Goto K. Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry). Lung cancer (Amsterdam, Netherlands), 202:108479, 2025

20. Takei S, Kotani D, Laliotis G, Sato K, Fujiwara N, Kawazoe A, Hashimoto T, Mishima S, Nakayama I, Nakamura Y, Bando H, Kuboki Y, Sakashita S, Spickard E, George GV, Dutta P, Sharma S, Malhotra M, Sethi H, Jurdi A, Liu MC, Yoshino T, Shitara K, Kojima T, Fujita T. Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study. Annals of surgery, 2025

21. Shimotsuura Y, Ishizuka K, Kawaguchi T, Umetsu K, Harada M, Inoue Y, Kubo E, Kosugi K, Igarashi T, Enomoto S, Taniyama H, Iwata T, Yamaguchi T, Matsumoto Y, Miura T. Effects of High-Resolution Natural Sound with Inaudible High-Frequency Components on Healing, Symptoms, and Sleep Satisfaction in Terminally Ill Cancer Patients. Palliative medicine reports, 6:53-60, 2025

22. Kano Y, Yamamoto Y, Ikematsu H, Sasabe M, Minakata N, Watanabe T, Yamashita H, Mitsui T, Inaba A, Sunakawa H, Nakajo K, Murano T, Kadota T, Shinmura K, Yano T. Investigation of vertical margin involvement in endoscopic resection for T1 colorectal cancer. Digestive endoscopy, 36:455-462, 2024

23. Ito S, Hotta K, Sekiguchi M, Takeuchi Y, Oka S, Yamamoto H, Shinmura K, Harada K, Uraoka T, Hisabe T, Sano Y, Kondo H, Horimatsu T, Kikuchi H, Kawamura T, Nagata S, Yamamoto K, Tajika M, Tsuji S, Kusaka T, Okuyama Y, Yoshida N, Moriyama T, Hasebe A, So S, Saito Y, Nakahira H, Ishikawa H, Matsuda T. Short-term outcomes of endoscopic resection for colorectal neuroendocrine tumors: Japanese multicenter prospective C-NET STUDY. Digestive endoscopy, 36:942-951, 2024

24. Noda S, Yamaguchi J, Kosugi K, Ishida A, Harada M, Ishizuka K, Inoue Y, Kubo E, Miura T. Peppermint Inhalation Therapy for Persistent Hiccups in Terminally Ill Cancer Patient: A Case Study. Journal of pain and symptom management, 67:e503-e505, 2024

25. Amano K, Okamura S, Baracos V, Mori N, Sakaguchi T, Uneno Y, Hiratsuka Y, Hamano J, Miura T, Ishiki H, Yokomichi N, Hatano Y, Morita T, Mori M. Fluid retention and weight loss in refractory cancer cachexia. BMJ supportive & palliative care, spcare-2024-004820, 2024

26. Sekiguchi M, Kishida Y, Ikematsu H, Konno M, Mizuguchi Y, Hotta K, Imai K, Ito S, Takada K, Shiomi A, Yasui H, Tsukamoto S, Hirano H, Kobayashi N, Saito Y, Inaba A, Shinmura K, Konishi J, Ozawa H, Fujita S, Murakami Y, Matsuda T. Proportions and characteristics of interval cancer in annual fecal immunochemical test screening and postcolonoscopy colorectal cancer: Results from a Japanese multicenter prospective study using questionnaires, the C-DETECT study. Digestive endoscopy, 36:1140-1151, 2024

27. Amano K, Baracos VE, Mori N, Okamura S, Yamada T, Miura T, Tatara R, Kessoku T, Matsuda Y, Tagami K, Otani H, Mori M, Taniyama T, Nakajima N, Nakanishi E, Kako J, Morita T, Miyashita M. Associations of nutrition impact symptoms with dietary intake and eating-related distress in patients with advanced cancer. Clinical nutrition ESPEN, 60:313-319, 2024

28. Amano K, Okamura S, Baracos VE, Mori N, Sakaguchi T, Uneno Y, Hiratsuka Y, Hamano J, Miura T, Ishiki H, Yokomichi N, Hatano Y, Morita T, Mori M. Impacts of fluid retention on prognostic abilities of cachexia diagnostic criteria in cancer patients with refractory cachexia. Clinical nutrition ESPEN, 60:373-381, 2024

29. Furue Y, Yoda Y, Hori K, Nakajo K, Kadota T, Murano T, Shinmura K, Ikematsu H, Yano T. Outcomes of repeated endoscopic submucosal dissection for superficial Esophageal squamous cell carcinoma on endoscopic resection scar. Diseases of the esophagus, 37:doae018, 2024

30. Hirota S, Tateishi U, Nakamoto Y, Yamamoto H, Sakurai S, Kikuchi H, Kanda T, Kurokawa Y, Cho H, Nishida T, Sawaki A, Ozaka M, Komatsu Y, Naito Y, Honma Y, Takahashi F, Hashimoto H, Udo M, Araki M, Nishidate S. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International journal of clinical oncology, 29:647-680, 2024

31. Okamura N, Kubo E, Ishida A, Noda S, Harada M, Ishizuka K, Inoue Y, Kosugi K, Miura T. Differences in discharge letter content: oncologists' vs. home care physicians' needs. Supportive care in cancer, 32:299, 2024

32. Kuboki Y, Koyama T, Matsubara N, Naito Y, Kondo S, Harano K, Yonemori K, Yoh K, Gu Y, Mita T, Chen X, Ueda E, Yamamoto N, Doi T, Shimizu T. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study. Cancer medicine, 13:e6980, 2024

33. Okahisa M, Udagawa H, Matsumoto S, Kato T, Yokouchi H, Furuya N, Kanemaru R, Toyozawa R, Nishiyama A, Ohashi K, Miyamoto S, Nishino K, Nakamura A, Iwama E, Niho S, Oi H, Sakai T, Shibata Y, Izumi H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Kah Mun Low G, Zhuo J, Goto K. Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands), 191:107798, 2024

34. Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. The Lancet. Oncology, 25:707-719, 2024

35. Tan RYC, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Han W, Im SA, Tan VKM, Phyu N, Wong FY, Tan PH, Yap YS. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study. Journal of the National Comprehensive Cancer Network : JNCCN, 22:e237121, 2024

36. Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D, Nakamura M, Hojo H, Sakashita S, Kinoshita T, Yano T, Mitsunaga S, Nishikawa H, Koyama S, Kojima T. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma. Journal of gastroenterology, 59:798-811, 2024

37. Yamamoto N, Kuboki Y, Harano K, Koyama T, Kondo S, Hagiwara A, Suzuki N, Fujikawa E, Toyoizumi K, Mukai M, Doi T. A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. Investigational new drugs, 42:376-385, 2024

38. Amano K, Okamura S, Matsuda Y, Baracos VE, Mori N, Miura T, Tatara R, Kessoku T, Tagami K, Otani H, Mori M, Taniyama T, Nakajima N, Nakanishi E, Kako J, Morita T, Miyashita M. Associations of nutrition impact symptoms with depression in patients with advanced cancer. Supportive care in cancer, 32:445, 2024

39. Inaba A, Shinmura K, Matsuzaki H, Takeshita N, Wakabayashi M, Sunakawa H, Nakajo K, Murano T, Kadota T, Ikematsu H, Yano T. Smartphone application for artificial intelligence-based evaluation of stool state during bowel preparation before colonoscopy. Digestive endoscopy, 36:1338-1346, 2024

40. Yamamoto N, Kitano S, Koyama T, Ikeda M, Mizugaki H, Narikiyo T, Yamaguchi Y, Ishida T, Takubo R, Ogami C, Sekiya M, Nakagawa Y, Kuboki Y. Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers. Journal for immunotherapy of cancer, 12:e009262, 2024

41. Krämer A, Bochtler T, Pauli C, Shiu KK, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomášek J, Arslan C, Özgüroğlu M, Stahl M, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Durán-Pacheco G, Michaud C, Scarato J, Thomas M, Ross JS, Moch H, Mileshkin L. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet (London, England), 404:527-539, 2024

42. Fukuda M, Mukohara T, Kuwata T, Sunami K, Naito Y. Efficacy of Trametinib in Neurofibromatosis Type 1-Associated Gastrointestinal Stromal Tumors: A Case Report. JCO precision oncology, 8:e2300649, 2024

43. Nakao T, Harano K, Wakabayashi M, Naito Y, Tanabe H, Mukohara T. Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance. Gynecologic oncology reports, 55:101482, 2024

44. Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature medicine, 30:3272-3283, 2024

45. Kataoka K, Mori K, Nakamura Y, Watanabe J, Akazawa N, Hirata K, Yokota M, Kato K, Kotaka M, Yamazaki K, Kagawa Y, Mishima S, Ando K, Miyo M, Yukami H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kotani D, Bando H, Taniguchi H, Takemasa I, Kato T, Yoshino T, Oki E. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Annals of oncology, 35:1015-1025, 2024

46. Naito Y, Nakamura S, Kawaguchi-Sakita N, Ishida T, Nakayama T, Yamamoto Y, Masuda N, Matsumoto K, Kogawa T, Sudo K, Shimomura A, Lai C, Zhang D, Iwahori Y, Gary D, Huynh D, Iwata H. Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International journal of clinical oncology, 29:1684-1695, 2024

47. Inaba A, Ikematsu H, Kojima M, Sakamoto N, Wakabayashi M, Sunakawa H, Nakajo K, Murano T, Kadota T, Shinmura K, Yano T. Association between pathological T1 colorectal cancer with lymphoid follicular replacement and risk of lymph node metastasis. Journal of gastroenterology and hepatology, 39:2631-2638, 2024

48. Minakata N, Kadota T, Sakashita S, Inaba A, Sunakawa H, Takashima K, Nakajo K, Murano T, Shinmura K, Yoda Y, Ikematsu H, Fujita T, Kinoshita T, Yano T. Tumor thickness is associated with metastasis in patients with submucosal invasive adenocarcinoma of the esophagogastric junction. Diseases of the esophagus, 37:doae083, 2024

49. Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia. Lung cancer (Amsterdam, Netherlands), 197:107992, 2024

50. Shimizu Y, Hayashi A, Maeda I, Miura T, Inoue A, Takano M, Aoyama M, Masukawa K, Miyashita M. Resilience and coping styles in family caregivers of terminally ill patients: A cross-sectional survey. Palliative & supportive care, 23:e12, 2024

51. Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, Hirano H, Ohtsubo K, Ohta T, Oki E, Nishina T, Yasui H, Kawakami H, Esaki T, Machida N, Doi A, Boku S, Kudo T, Yamamoto Y, Kanazawa A, Denda T, Goto M, Iida N, Ozaki H, Shibuki T, Imai M, Fujisawa T, Bando H, Naito Y, Yoshino T. Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors. BJC reports, 2:54, 2024

Book

1. Nakajima H, Mukohara T. Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer. In: Bonavida B (ed), Overcoming Cancers Resistant to HER-2 Antibodies: Breaking Tolerance to Antibody-Mediated Immunotherapy, United Kingdom, Academic Press, pp 45-56, 2024